• Company Type For Profit

Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity

ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.

Lists Featuring This Company

Enterprise Equity Portfolio Companies
41 Number of Organizations • $509.4M Total Funding Amount • 176 Number of Investors
Closed United Kingdom Companies (Top 10K)
9,639 Number of Organizations • $21.5B Total Funding Amount • 4,410 Number of Investors
Closed Biotechnology Companies
3,634 Number of Organizations • $76.5B Total Funding Amount • 6,411 Number of Investors
Closed Europe, Middle East, and Africa (EMEA) Biotechnology Companies
830 Number of Organizations • $7.4B Total Funding Amount • 1,199 Number of Investors

Frequently Asked Questions

Where is Gendel's headquarters? Gendel is located in Coleraine, Coleraine, United Kingdom.Who invested in Gendel? Gendel has 4 investors including Scottish Equity Partners and Enterprise Equity.How much funding has Gendel raised to date? Gendel has raised .When was the last funding round for Gendel? Gendel closed its last funding round on May 25, 2005 from a Venture - Series Unknown round.